Session Details
[28ISP]Interdisciplinary Session Poster: Nucleic acids/DDS/Vaccines
Tue. Mar 28, 2023 9:00 AM - 3:50 PM JST
Tue. Mar 28, 2023 12:00 AM - 6:50 AM UTC
Tue. Mar 28, 2023 12:00 AM - 6:50 AM UTC
[Room P3] Frontier Research in Applied Sciences Building: Foyer 2F
Discussion time: 15:10-15:50
[28ISP-01]Preparation, Formulation of Characterization and Stability Studies of Rhodiola Rosea Nanoemulsion using Low Energy Method for Topical Drug Delivery System
○Benni Iskandar1,2, Hsiu-Mei Lin3, Ching-Kuo Lee2 (1. Department of Pharmaceutical Technology, Sekolah Tinggi Ilmu Farmasi Riau (STIFAR), Pekanbaru, Riau, Indonesia, 28292, 2. School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan, 11031, 3. National Taiwan Ocean University, Department of Bioscience and Biotechnology, Keelung 202, Taiwan)
[28ISP-02]DSC of physical mixtures as a primary indicator for amorphous solid dispersion formation
○So Hyeon Lim1, Jung Min Yun1, Ae Ri Kim1 (1. College of Pharmacy, CHA University, Seongnam, 463-400, Republic of Korea)
[28ISP-03 (26E4-pm18S)]Development of LNA-phosphoramidites to improve the elongation efficiency in oligonucleotide synthesis
○Ayaka Ichikawa1, Takashi Osawa2, Satoshi Obika2,3,4 (1. Sch. Pharm. Sci., Osaka Univ., 2. Grad. Sch. Pharm. Sci., Osaka Univ., 3. NIBIOHN, 4. OTRI)
[28ISP-04 (26E4-pm19S)]Post-synthetic nucleobase modification of oligonuceotides by Sonogashira reaction and the effects on duplex stability
○Atsushi Mikami1, Shohei Mori1, Takashi Osawa1, Satoshi Obika1,2,3 (1. Grad. Sch. Pharm. Sci., Osaka Univ., 2. NIBIOHN, 3. OTRI)
[28ISP-05 (26E4-pm20S)]Synthesis of Guanine Derivative of 2'-O,4'-C-Spirocyclopentylene-Bridged Nucleic Acid
○Riku Kumagai1, Takaya Sugiura2, Hibiki Komine2, Takao Yamaguchi2, Satoshi Obika2,3,4 (1. Sch. Pharm. Sci., Osaka Univ., 2. Grad. Sch. Pharm. Sci., Osaka Univ., 3. NIBIOHN, 4. OTRI)
[28ISP-06 (26E4-pm21S)]Synthesis and Properties of 2′-O-methyl-5-methyluridine Derivative bearing a 1–Oxaspiro[4.5]decane Skeleton
○Sayoko Ito1, Natsumi Yano2, Takashi Osawa2, Satoshi Obika2,3,4 (1. Sch. Pharm. Sci., Osaka Univ., 2. Grad. Sch. Pharm. Sci., Osaka Univ., 3. NIBIOHN, 4. OTRI)
[28ISP-07 (26B2-am13S)]Enzymatic synthesis of modified oligonucleotides with extended random region
○Kaito Nitatouge1,2, Kenta Ishida2,3, Hidekazu Hoshino2, Yuuya Kasahara2,3, Satoshi Obika2,3,4 (1. Sch. Pharm. Sci., Osaka Univ., 2. NIBIOHN, 3. Grad. Sch. Pharm. Sci., Osaka Univ. , 4. OTRI, Osaka Univ.)
[28ISP-08 (26B2-am14)]The effect of polyamines on XNA synthesis by polymerases
○Hidekazu Hoshino1, Yuuya Kasahara1,2, Satoshi Obika1,2,3 (1. NIBIOHN, 2. Grad. Sch. Pharm. Sci., Osaka Univ., 3. OTRI, Osaka Univ.)
[28ISP-09 (26B2-am15S)]Development of anti-CHIP/STUB1 aptamers containing sugar- and base-modified nucleic acids
○Kenta Ishida1,2, Youko Senga2, Kaito Nitatouge3, Masahiro Oka2, Nobumichi Ohoka4, Hidekazu Hoshino2, Yosuke Demizu4, Takao Inoue4, Satoshi Obika1,2,5, Yuuya Kasahara1,2 (1. Grad. Sch. Pharm. Sci., Osaka Univ., 2. NIBIOHN, 3. Sch. Pharm. Sci., Osaka Univ., 4. NIHS, 5. OTRI, Osaka Univ.)
[28ISP-10 (26B2-am10)]Development of Dendritic Multivalent Oligonucleotides for Therapeutics
○Yusuke Kawamoto1, You Wu1, Soyoung Park2, Hiroshi Sugiyama3,4, Yuki Takahashi1, Yoshinobu Takakura1 (1. Grad. Sch. Pharm., Kyoto Univ., 2. IFReC, Osaka Univ., 3. Grad. Sch. Sci., Kyoto Univ., 4. iCeMS, Kyoto Univ.)
[28ISP-11 (27B2-pm13S)]Synthesis and evaluation of in vitro and in vivo properties of ASOs conjugated with divalent PEGs
○TAHIA TAUFIQ1,2, Taslima Rahman Chowdhury1,2, Md Ariful Islam1, Yuuya Kasahara1,2, Taisuke Nakayama2, Haruhiko Kamada2, Takashi Osawa1, Satoshi Obika1,2,3 (1. Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan, 2. National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan, 3. Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University, 1-3 Yamadaoka, Suita, Osaka 565-0871, Japan)
[28ISP-12 (27P1-pm2-086)]Effect of 5’-Modification on the Asymmetry Recognition of siRNA and the Elimination of Off-Target Effect
○Masayuki Fujii1, Yojiro Kotake1, Yasuo Shiohama2 (1. Sci Tech., Kindai University, 2. Sch. Med., University of Yamaguchi)
[28ISP-13 (26E2-pm07)]Antitumor effect of lipid-siRNAs for pancreatic cancer in a liver-metastatic tumor mouse model
○Takanori Kubo1, Rina Tansou1, Yoshio Nishimura2, Keishiro Mihara3, Kazuyoshi Yanagihara4, Toshio Seyama1 (1. Fac. Pharm., Yasuda Women’s Univ, 2. Sch. Pharm. Sci., Ohu Univ., 3. Fujita Health Univ., 4. Nat. Can. Cen.)
[28ISP-14 (26E2-pm09S)]Design strategy for gapmer antisense oligonucleotides to improve antisense activity
○Chihiro Oda1,2, Yuuya Kasahara2,3, Harumi Yamaguma2, Masahito Shimojo3, Satoshi Obika2,3,4 (1. Sch. Pharm. Sci., Osaka Univ., 2. NIBIOHN, 3. Grad. Sch. Pharm. Sci., Osaka Univ., 4. OTRI, Osaka Univ.)
[28ISP-15 (26E2-pm08)]Effectiveness evaluation of SHAPE-MaP analysis for antisense oligonucleotides design
○Yuuya Kasahara1,2, Natsumi Kameoka1, Harumi Yamaguma1, Satoshi Obika1,2,3 (1. NIBIOHN, 2. Grad. Sch. Pharm. Sci., Osaka Univ., 3. OTRI, Osaka Univ.)
[28ISP-16 (26M3-am12)]Development of star-shaped phospholipid polymers for nucleic acid delivery
○Yuta Yoshizaki1, Tomohiro Konno1 (1. Grad. Sch. of Pharm. Sci., Tohoku Univ.)
[28ISP-17 (28P2-am1-026)]Structural study of the nuclear transporting mechanism of ZFTA-RelA fusion protein
○Sachiko Toma-Fukai1,2, Hiroaki Matsuura3, Naoki Sakai3, Kunio Hirata3, Yuki Matsuya2, Hikaru Shimizu2, Koki Hayama1, Shoma Imamura1, Ruri Kojima4, Toshiyuki Shimizu2, Hironari Kamikubo1, Daisuke Kawauchi5, Shinya Ohata2,4 (1. Grad. Sch. Sci. and Tech., NAIST, 2. Grad. Sch. Pharm. Sci., The Univ. of Tokyo, 3. RSC, 4. Musashino Univ., 5. NCNP)
[28ISP-18 (26M3-am01)]Separation of 100 nm-sized nanoparticles based on their surface properties using poly-Lys modified monolith column
○Masaru Kato1, Yuka Kanai1, Yuuki Manda1, Eiichi Yamamoto2, Shota Miyazaki3, Chiaki Aoyama3, Masatoshi Akitake3, Shigenori Ohta3 (1. Sch. Pharm., Showa Univ., 2. National Institute of Health Sciences, 3. GL Sciences Inc.)
[28ISP-19 (26P1-pm1-103S)]Preparation of a novel lipid nanoparticle using a apolipoprotein A-I-derived peptide
○Yu Mizukami1, Ryo Kawakami1, Rumina Shima1, Shiori Shibukawa1, Ryosuke Fukuda1, Tatsuya Murakami1,2 (1. Grad. Sch. Eng., Toyama Pref. Univ., 2. iCeMS, Kyoto Univ.)
[28ISP-20 (27C2-am01S)]Development of gapmer antisense oligonucleotide for transcriptional repressor REST that causes several malignant brain tumors
○Yusuke Tamenori1, Satoshi Obika2,3,4, Masahito Shimojo2 (1. Sch. Pharm. Sci., Osaka Univ., 2. Grad. Sch. Pharm. Sci., 3. OTRI, Osaka Univ., 4. NIBIOHN)
[28ISP-21 (27C2-am02S)]Pharmacokinetics of the antisense oligonucleotide SRRM4-ASO for the treatment of small cell lung cancer
○Ryota Suginaka1, Satoshi Obika1,2,3, Masahito Shimojo1 (1. Grad. Sch. Pharm. Sci., Osaka Univ, 2. NIBIOHN, 3. OTRI)
[28ISP-22 (27C2-am03S)]Study of cellular uptake of antisense oligonucleotide using TRPC3/TRPC6 activator
○Hiroto Kohashi1, Ryu Nagata1, Satoshi Obika1,2,3, Masahito Shimojo1 (1. Grad. Sch. Pharm. Sci., Osaka Univ., 2. OTRI, Osaka Univ., 3. NIBIOHN)
[28ISP-23 (26E5-pm07)]How does p300 propagate histone acetylation?
Masaki Kikuchi1, Satoshi Morita1, Masatoshi Wakamori1, Shin Sato1, Tomomi Uchikubo-Kamo1, Mikako Shirouzu1, ○Takashi Umehara1 (1. RIKEN)
[28ISP-24 (26P2-pm2-007)]Characterization of α-helical peptides to increase unmethylated CpG DNA-induced macrophage activation
○Saeka Nishihara1, Nao Nakamura1, Kiyoshi Kawasaki1 (1. DWCLA)
[28ISP-25 (26P2-pm2-117)]Study on in vivo metabolism of antisense oligonucleotides modified with bridged nucleic acids using LC-MS/MS
○Takahiro Kikuchi1, Satoshi Itou1, Shun Kumagaya2, Kosuke Chiba2, Masaki Yamagami2, Kenta Hashizume1 (1. Drug Development Solutions Center, Sekisui Medical Co., Ltd., 2. Research and Development Division, Luxna Biotech Co., Ltd.)
[28ISP-26]Development of liposome cancer drug FF-10832 (PEGylated Gemcitabine liposome) and FF-10850 (PEGylated Toptecan liposome), application of the CMC technologies for liposome CDMO services
○Mikinaga Mori1, Shiro Sonoke1, Kohei Ono1 (1. FUJIFILM Corporation)
[28ISP-27 (27P2-am1-059S)]Inflammation-induced engineered macrophages for efficient cancer therapy
○Kenta Tanito1, Yuta Yokoyama1, Haruka Oishi2, Mayuka Shibata2, Shoichi Hijii2, Ryosuke Kaneko2, Chuya Tateishi1, Shoko Ito2, Akihiro Kishimura1,2,3, Takeshi Mori1,2, Teruki Nii1,2, Yoshiki Katayama1,2,3 (1. Grad. Sch. Syst. Life Sci., Kyushu Univ., 2. Grad. Sch. Engineering, Kyushu University, 3. Int. Res. Center for Mol. Syst., Kyushu Univ.)
[28ISP-28 (27P2-am1-070)]Construction of AAV Delivery Systems Based on Phenylboronic Acid-Conjugated Polymers and Polyphenol Molecules for Brain-Selective Gene Expression
○Yuto Honda1,2,3, Shuhei Nagao1,2, Nozomi Matsudaira1,2, Hiroaki Kinoh3, Takahiro Nomoto1,2, Yutaka Miura1,2, Nobuhiro Nishiyama1,2,3 (1. Lab. for Chem. and Life Sci., Tokyo Tech., 2. Dept. of Life Sci. and Tech., Tokyo Tech., 3. Innovation Center of NanoMedicine)
[28ISP-29 (27P2-am1-073)]Characterization of lipid nanoparticle-nucleic acid complexes by experimental methods and molecular simulations
Kasumi Sasaki1, Koji Okuwaki1, Takayuki Furuishi1, Kenjiro Higashi2, ○Kaori Fukuzawa1,3, Etsuo Yonemochi1 (1. Grad. Sch. Pharm. Sci., Hoshi Univ., 2. Grad. Sch. Pharm. Sci., Chiba Univ., 3. Grad. Sch. Pharm. Sci., Osaka Univ.)
[28ISP-30 (26PS3-am02S)]Development of temperature-responsive polyion complexes capable of sustained release of micelles containing oligonucleotides
○Ziwei Ma1, Hiroshi Kamizawa1, Rento Ota1, Teruki Nii2, Takeshi Mori2,3, Yoshiki Katayama2,3,4,5, Akihiro Kishimura2,3,4,6 (1. Grad. Sch. Sys. Life Sci., Kyushu Univ., 2. Dept. of Applied Chem., Fac. of Eng., Kyushu Univ., 3. Ctr. for Future Chem., Kyushu Univ., 4. Ctr. for Molecular Systems, Kyushu Univ., 5. Ctr. for Adv. Med. Innov., Kyushu Univ., 6. RIKEN Ctr. for Emergent Matter Sci.)
[28ISP-31 (27P2-am1-071S)]Intracellular delivery of mRNA drugs using chemically modified dendrimers
○Moeka Hata1, Shota Oyama2, Tsuyoshi Yamamoto2, Hiroaki Kitagishi3, Shigeru Kawakami2, Hidetoshi Arima4, Asako Yamayoshi2 (1. Sch. Pharm. Sci., Nagasaki Univ., 2. Grad. Sch. Biomed. Sci., Nagasaki Univ., 3. Fac. Sci. Eng., Doshisha Univ., 4. Sch. Pharm., Daiichi Univ.)
[28ISP-32 (26PS3-am07S)]Structure and interaction evaluation of ssPalm lipid nanoparticle using computational chemistry
○Naoko Konami1, Karen Ujiie1, Kasumi Sasaki1, Koji Okuwaki1, Hiroki Tanaka2, Hidetaka Akita3, Takayuki Furuishi1, Kaori Fukuzawa1,4, Etsuo Yonemochi1 (1. Sch. Pharm., Hoshi Univ., 2. Grad. Sch. Pharm. Sci., Chiba Univ., 3. Grad. Sch. Pharm. Sci., Tohoku Univ., 4. Grad. Sch. Pharm. Sci., Osaka Univ.)
[28ISP-33 (27P2-am1-072S)]Development of cyclic peptide loaded ternary complex to enhance the gene expression selectivility of adeno associated virus (AAV) in tumor
○Nozomi Matsudaira1,2, Yuto Honda1,2, Syuhei Nagao1,2, Hiroaki Kinoh3, Takahiro Nomoto1,2, Xueying Liu 3, Anjaneyulu Dirisala 3, Yutaka Miura1,2, Kazunori Kataoka3, Nobuhiro Nishiyama1,2 (1. Department of Life Science and Technology, School of Life Science and Technology, Tokyo Institute of Technology, 2. Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 3. Innovation Center of Nanomedicine (iCONM), Kawasaki Institute of Industrial Promotion)
[28ISP-34 (27PS3-pm01S)]Application of electrospun nanofiber mats including D-mannitol to dry powder inhalers.
○Shintaro Tamashiro1, Takaaki Ito1, Eriko Yamazoe1, Kohei Tahara1 (1. Gifu Pharmaceutical University)
[28ISP-35 (27PS3-pm04)]Cyclosporine A-loaded respirable powder formulation with improved mucosal absorption: in silico pharmacokinetic prediction for efficient formulation development
○Kohei Yamada1, Atsushi Kambayashi1,2, Hideyuki Sato1, Satomi Onoue1 (1. Lab. of Biopharmacy, Sch. of Pharm. Sci., Univ. of Shizuoka, 2. Pharmaceutical Research and Technology Labs, Astellas Pharma. Inc.)
[28ISP-36 (27PS3-pm07)]Development of novel biodegradable oil gelling agents by ester bonding various fatty acids to 1,5-anhydro-D-glucitol (1,5-AG) derived from starch
○Shiro Komba1, Rika Iwaura1, Takahito Kajiki2 (1. National Agriculture and Food Research Organization, 2. SUNUS CO., LTD )
[28ISP-37 (27PS3-pm08S)]Assessment of the properties as immuno-stimulator of the nanoparticles derived from glycyrrhiza and analysis of its mechanism
○Yuno Suzuki1, Lisa Munakata1, Daiki Omata1, Keiichi Koizumi2, Ryo Suzuki1,3 (1. Fac. Pharma-Sci., Teikyo Univ., 2. Inst. Nat. Med., Univ. Toyama, 3. ACRO, Teikyo Univ.)
[28ISP-38 (28P2-am2-145)]Study aimed at standardization of Microphysiological systems(MPS) as new human-type in vitro drug evaluation test systems
○yukari shigemoto-mogami1, kimiko nakayama-kitamura1, Tomomi Furihata2, hitoshi naraoka3,4, Michiya Matsusaki5, ddaiju yamazaki1, seiichi ishida1,6, kaoru sato1 (1. NIHS Divi. Pharmacol., 2. Tokyo Univ. Pharm. Life Sci.,, 3. Astellas Pharma Inc. , 4. SCA, 5. Grad. Sch. Eng. Sci., Osaka Univ. , 6. Grad. Sch. Eng. Sci., Sojo Univ. )